Novartis also reported inconsistent bottle-packaging practices at the company's Lincoln, Neb., facility, which could result in the bottles containing foreign tablets, caplets or capsules, the U.S. Food and Drug Administration said Monday.
"Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient," the FDA said in a statement. "This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient."
The voluntary recall includes all lots of select bottle-packaging configurations from retailers of Excedrin and NoDoz products with expiration dates of Dec. 20, 2014, or earlier, and Bufferin and Gax-X products with expiration dates of Dec. 20, 2013, or earlier.
Swim Week Miami Beach 2014 [PHOTOS]